Hologic, Inc. (NASDAQ:HOLX) – Research analysts at Leerink Swann issued their Q1 2018 EPS estimates for Hologic in a report released on Thursday. Leerink Swann analyst R. Newitter expects that the medical equipment provider will earn $0.52 per share for the quarter. Leerink Swann also issued estimates for Hologic’s Q2 2018 earnings at $0.52 EPS, Q3 2018 earnings at $0.57 EPS and Q4 2018 earnings at $0.55 EPS.
HOLX has been the subject of several other reports. Royal Bank Of Canada lowered their price objective on shares of Hologic from $50.00 to $45.00 and set a “sector perform” rating for the company in a research report on Thursday, August 3rd. BidaskClub downgraded shares of Hologic from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, July 25th. Zacks Investment Research upgraded shares of Hologic from a “sell” rating to a “hold” rating in a research report on Friday, August 4th. Barclays PLC lowered their price objective on shares of Hologic from $53.00 to $51.00 and set an “overweight” rating for the company in a research report on Thursday, August 3rd. Finally, Needham & Company LLC restated a “buy” rating on shares of Hologic in a research report on Tuesday, August 1st. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and nine have given a buy rating to the company’s stock. Hologic presently has an average rating of “Hold” and a consensus price target of $47.77.
ILLEGAL ACTIVITY WARNING: “Hologic, Inc. (HOLX) Forecasted to Post Q1 2018 Earnings of $0.52 Per Share” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2017/10/27/hologic-inc-holx-forecasted-to-post-q1-2018-earnings-of-0-52-per-share.html.
Hologic (NASDAQ:HOLX) traded up 0.49% during midday trading on Monday, reaching $36.99. The company had a trading volume of 844,391 shares. Hologic has a one year low of $35.15 and a one year high of $46.80. The stock’s 50 day moving average is $37.64 and its 200 day moving average is $41.89. The company has a market capitalization of $10.37 billion, a PE ratio of 13.78 and a beta of 0.91.
Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Wednesday, August 2nd. The medical equipment provider reported $0.50 EPS for the quarter, topping the Zacks’ consensus estimate of $0.49 by $0.01. The business had revenue of $806.10 million for the quarter, compared to analyst estimates of $799.70 million. Hologic had a return on equity of 23.18% and a net margin of 25.65%. Hologic’s revenue for the quarter was up 12.4% on a year-over-year basis. During the same period in the prior year, the company earned $0.51 EPS.
Several institutional investors have recently modified their holdings of the stock. Curbstone Financial Management Corp grew its stake in shares of Hologic by 101.2% in the third quarter. Curbstone Financial Management Corp now owns 17,456 shares of the medical equipment provider’s stock worth $640,000 after purchasing an additional 8,778 shares during the last quarter. MPS Loria Financial Planners LLC bought a new stake in shares of Hologic in the second quarter worth $191,000. Lord Abbett & CO. LLC grew its stake in shares of Hologic by 78.8% in the second quarter. Lord Abbett & CO. LLC now owns 432,716 shares of the medical equipment provider’s stock worth $19,637,000 after purchasing an additional 190,714 shares during the last quarter. USA Financial Portformulas Corp bought a new stake in shares of Hologic in the second quarter worth $2,949,000. Finally, Hall Laurie J Trustee grew its stake in shares of Hologic by 10.2% in the second quarter. Hall Laurie J Trustee now owns 2,425 shares of the medical equipment provider’s stock worth $110,000 after purchasing an additional 225 shares during the last quarter. 96.38% of the stock is currently owned by institutional investors.
In related news, Director Lawrence M. Levy sold 7,138 shares of the business’s stock in a transaction on Monday, October 9th. The shares were sold at an average price of $37.38, for a total value of $266,818.44. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Elaine Ullian sold 6,902 shares of the business’s stock in a transaction on Thursday, August 3rd. The stock was sold at an average price of $40.12, for a total transaction of $276,908.24. Following the completion of the sale, the director now directly owns 23,810 shares in the company, valued at approximately $955,257.20. The disclosure for this sale can be found here. In the last three months, insiders sold 30,775 shares of company stock worth $1,175,662. 0.79% of the stock is currently owned by insiders.
Hologic Company Profile
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.